Year |
Citation |
Score |
2020 |
DeJong S, Hou X, Zanfagnin V, Evans B, VanBlaricom J, Epler J, Nickles D, Becker M, Oberg A, Heinzen E, Blackwood B, Haluska P, Weroha S. Gemcitabine and novel Chk1 inhibitor GDC-0575 demonstrate synergistic effect against high-grade serous ovarian cancer in 3D cell culture, PDX models and patient tumors Gynecologic Oncology. 159: 90. DOI: 10.1016/j.ygyno.2020.05.072 |
0.307 |
|
2018 |
Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, et al. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. Journal of the National Cancer Institute. PMID 29788332 DOI: 10.1093/Jnci/Djy033 |
0.303 |
|
2017 |
Butler KA, Hou X, Becker MA, Zanfagnin V, Enderica-Gonzalez S, Visscher D, Kalli KR, Tienchaianada P, Haluska P, Weroha SJ. Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts. Neoplasia (New York, N.Y.). 19: 628-636. PMID 28658648 DOI: 10.1016/J.Neo.2017.04.007 |
0.398 |
|
2017 |
Zanfagnin V, Bale LK, Becker MA, Hou X, Torres D, Conover CA, Weroha SJ. Abstract 4817: Regression of malignant ascites via PAPP-A inhibition in ovarian cancer patient-derived xenograft model Cancer Research. 77: 4817-4817. DOI: 10.1158/1538-7445.Am2017-4817 |
0.448 |
|
2016 |
Becker MA, Hou X, Tienchaianada P, Haines BB, Harrington SC, Weroha SJ, Sathyanarayanan S, Haluska P. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer. Bmc Cancer. 16: 814. PMID 27765027 DOI: 10.1186/S12885-016-2847-3 |
0.566 |
|
2016 |
AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, et al. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecologic Oncology. PMID 27614696 DOI: 10.1016/J.Ygyno.2016.08.328 |
0.318 |
|
2016 |
Martchenko K, Schmidtmann I, Thomaidis T, Thole V, Galle PR, Becker M, Möhler M, Wehler TC, Schimanski CC. Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. World Journal of Gastroenterology. 22: 5400-5. PMID 27340356 DOI: 10.3748/Wjg.V22.I23.5400 |
0.444 |
|
2016 |
Becker MA, Ibrahim YH, Oh AS, Fagan DH, Byron SA, Sarver AL, Lee AV, Shaw LM, Fan C, Perou CM, Yee D. Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. Plos One. 11: e0150564. PMID 26991655 DOI: 10.1371/Journal.Pone.0150564 |
0.717 |
|
2016 |
Long B, Hou X, Becker M, VanBlaricom J, Bradley E, Hendrickson AEW, Oberg AL, Maurer MJ, Heinzen E, Camoriano JK, Colon-Otero G, Burton JK, Kalli K, Foster NR, Haluska P, et al. MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps5609 |
0.442 |
|
2016 |
Harris FR, Halling GC, Becker MA, Haluska P, Vasmatzis G, Kovtun IV. Abstract 13: Individualized approach for ovarian cancer: Identification of potential therapeutic targets based on genomic analyses, testing efficiency of treatments, and monitoring Clinical Cancer Research. 22: 13-13. DOI: 10.1158/1557-3265.Pmsclingen15-13 |
0.425 |
|
2016 |
Nitschmann CC, Hurley RM, Becker MA, Hou X, Hoch U, Harding TC, Charych DH, Kaufmann SH, Haluska P, Weroha SJ. Abstract B50: Antineoplastic activity of Top I inhibitor etirinotecan pegol (NKTR-102) and PARP inhibitor rucaparib (CO-388) in platinum-resistant high-grade serous BRCA WT ovarian cancer PDX models. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B50 |
0.481 |
|
2015 |
Glaser G, Weroha SJ, Becker MA, Hou X, Enderica-Gonzalez S, Harrington SC, Haluska P. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. Plos One. 10: e0126867. PMID 25962155 DOI: 10.1371/Journal.Pone.0126867 |
0.487 |
|
2015 |
Becker MA, Haluska P, Bale LK, Oxvig C, Conover CA. A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts. Molecular Cancer Therapeutics. 14: 973-81. PMID 25695953 DOI: 10.1158/1535-7163.Mct-14-0880 |
0.534 |
|
2015 |
Wilcoxen KM, Becker M, Neff C, Abkevich V, Jones JT, Hou X, Wang Y, Hartman A, AlHilli MM, Gutin A, Agarwal S, Timms K, Haluska P. Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors. Journal of Clinical Oncology. 33: 5532-5532. DOI: 10.1200/Jco.2015.33.15_Suppl.5532 |
0.353 |
|
2015 |
Kumar A, Weroha S, Becker M, Hou X, Greiner S, Karnitz L, Haluska P. Abstract POSTER-THER-1419: Chk1 inhibitor (MK8776) enhances cytotoxicity of gemcitabine in select patient-derived ovarian tumorgraft models Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1419 |
0.384 |
|
2015 |
Lodhia KA, Becker MA, Hou X, Kalli KR, Harrell MI, Swisher EM, Weroha JS, Haluska P. Abstract 1474: Characterization of 148 ovarian cancer tumografts (Avatars) using BROCA-HR deep sequencing Cancer Research. 75: 1474-1474. DOI: 10.1158/1538-7445.Am2015-1474 |
0.464 |
|
2015 |
Becker M, Haluska P, Bale L, Oxvig C, Conover C. LBA1A Novel Neutralizing Antibody Targeting PAPP-A Inhibits Tumor Growth and Ascites in Primary Patient Ovarian Tumorgrafts (Ovatars) Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv098.1 |
0.504 |
|
2015 |
Lodhia K, Becker M, Hou X, Kalli K, Harrell M, Wilcoxen K, Swisher E, Weroha S, Halsuka P. Characterization of 148 Ovarian Cancer tumografts (Avatars) using BROCA-HR deep sequencing Annals of Oncology. 26: ii31. DOI: 10.1093/Annonc/Mdv096.1 |
0.414 |
|
2015 |
Kurokawa C, Iankov I, Aderca I, Maurer M, Anderson K, Greiner S, Becker M, Haluska P, Galanis E. 73. Effects of the Innate Immune System on Oncolytic Measles Virotherapy Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)33678-4 |
0.389 |
|
2015 |
Mills KA, Becker MA, Febbraro T, Litchfield LM, Lengyel E, Haluska P, Romero I. Advancing metformin as a metabolic therapeutic for ovarian cancer: Testing in non-diabetic patient-derived xenograft avatars Gynecologic Oncology. 137: 63. DOI: 10.1016/J.Ygyno.2015.01.148 |
0.353 |
|
2014 |
Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1288-97. PMID 24398046 DOI: 10.1158/1078-0432.Ccr-13-2611 |
0.442 |
|
2014 |
Hou X, Becker MA, Weroha SJ, Butler KA, Greiner SM, Haluksa P. Abstract 1196: Overexpression of IGF-2 in primary patient ovarian cancer tumorgrafts increases bowel and thoracic metastasis Cancer Research. 74: 1196-1196. DOI: 10.1158/1538-7445.Am2014-1196 |
0.506 |
|
2014 |
Becker M, Hou X, Haluska P. PO3-5: Developing predictive determinants of IGF/INS targeted therapies in ovarian cancer patient tumors and primary tumorgrafts Growth Hormone & Igf Research. 24: S31. DOI: 10.1016/S1096-6374(14)50081-0 |
0.413 |
|
2014 |
Haluska P, Timms K, AlHilli M, Wang Y, Hartman A, Jones J, Gutin A, Sangale Z, Neff C, Lynchbury J, Rudolph-Owen L, Becker M, Agarwal S, Wilcoxen K. 214 Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer European Journal of Cancer. 50: 72-73. DOI: 10.1016/S0959-8049(14)70340-5 |
0.304 |
|
2013 |
Scott CL, Becker MA, Haluska P, Samimi G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Frontiers in Oncology. 3: 295. PMID 24363999 DOI: 10.3389/Fonc.2013.00295 |
0.499 |
|
2013 |
Becker MA, Farzan T, Harrington SC, Krempski JW, Weroha SJ, Hou X, Kalli KR, Wong TW, Haluska P. Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth. Molecular Cancer Therapeutics. 12: 2909-16. PMID 24130056 DOI: 10.1158/1535-7163.Mct-13-0547 |
0.511 |
|
2013 |
Yang Y, Becker MA, Yee D. Abstract 535: IGF-I stimulates amino acid transporter xC- function to reduce intracellular ROS level and promote proliferation in human breast cancer cells. Cancer Research. 73: 535-535. DOI: 10.1158/1538-7445.Am2013-535 |
0.664 |
|
2013 |
Hilli MA, Weroha SJ, Becker M, Hou X, Harrington S, McKinstrey S, Kalli K, Goodman K, Wilcoxen K, Swisher E, Kaufmann S, Haluska P. Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-Pr05 |
0.486 |
|
2013 |
Weroha SJ, Haluska P, Becker MA, Harrington SC, Goodman KM, Gonzalez SE, Hilli Ma, Butler KA, Kalli KR, Oberg AL. L11.04Ovarian Avatar Models Predictive Of Platinum Response In Ovarian Cancer Patients Annals of Oncology. 24. DOI: 10.1093/Annonc/Mdt042.51 |
0.391 |
|
2012 |
Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, Jacob KA, Carboni JM, Gottardis MM, Haluska P. IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors Clinical Cancer Research. 18: 1808-1817. PMID 22287600 DOI: 10.1158/1078-0432.Ccr-11-1806 |
0.547 |
|
2012 |
Gonzalez SE, Weroha SJ, Becker M, Harrington S, Hou X, Haluska P. Abstract 3274: Development of a clinically relevantin vivomodel of ovarian cancer tumorgrafts in immunodeficient mice Cancer Research. 72: 3274-3274. DOI: 10.1158/1538-7445.Am2012-3274 |
0.448 |
|
2012 |
Becker M, Giri S, Finckenstein F, Lynch M, Gottardis M, Carboni J, Shridhar V, Haluska P. P01-9 BMS-754807 and metformin synergistically inhibit breast and ovarian cancer cell proliferation Growth Hormone & Igf Research. 22: S35-S36. DOI: 10.1016/S1096-6374(12)60090-2 |
0.389 |
|
2012 |
Hou X, Haines B, Harrington S, Becker M, Weroha J, Sathyanarayanan S, Haluska P. P01-4 Antitumor effect of ridaforolimus (MK-8669) in combination with dalotuzumab (MK-0646) and aromatase inhibitor letrozole in a postmenopausal breast cancer model Growth Hormone & Igf Research. 22. DOI: 10.1016/S1096-6374(12)60085-9 |
0.452 |
|
2012 |
Butler K, Weroha S, Becker M, Enderica-Gonzalez S, Harrington S, Hou X, Visscher D, Haluska P. Ovarian cancer tumorgraft: Viral latency propagates lymphoma Gynecologic Oncology. 127. DOI: 10.1016/J.Ygyno.2012.07.044 |
0.422 |
|
2011 |
Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. Molecular Endocrinology (Baltimore, Md.). 25: 516-28. PMID 21292829 DOI: 10.1210/me.2010-0373 |
0.647 |
|
2011 |
Rodriguez M, Becker M, Yee D, Potter D. P4-02-11: Insulin-Like Growth Factor I Promotes Estrogen Receptor Positive Breast Cancer Cell Proliferation, in Part, through CYP1A1 Signaling. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P4-02-11 |
0.526 |
|
2011 |
Becker M, Hou X, Harrington S, Carboni J, Gottardis M, Haluska P. P2-11-11: IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-11-11 |
0.549 |
|
2011 |
Yang Y, Becker M, Yee D. P2-03-03: An Insulin-Like Growth Factor I (IGF-I)-Induced Gene, Solute Carrier Family 7 Member 11 (SLC7A11)/xCT, Mediates IGF-I-Induced Biological Behaviors in Breast Cancer Cells. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-03-03 |
0.564 |
|
2010 |
Rodriguez M, Mitra R, Guo Z, Becker MA, Yee D, Potter DA. Abstract 4129: Effects of the metabolism of omega-3 fatty acid EPA by CYP1A1 in breast cancer proliferation and survival Cancer Research. 70: 4129-4129. DOI: 10.1158/1538-7445.Am10-4129 |
0.619 |
|
2009 |
Yee D, Fagan DH, Zhang X, Oh AS, LaPara K, Becker M, Sachdev D, Zhang H. Abstract CN07-02: Disrupting insulin‐like growth factor signaling with monoclonal antibodies Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-Cn07-02 |
0.741 |
|
2009 |
Becker M, Yee D. IGF-I mediated phosphorylation of ERαS167 occurs downstream of mTOR/p70S6K1 to impact nuclear localization and chromatin interaction. Cancer Research. 69: 6012. DOI: 10.1158/0008-5472.Sabcs-6012 |
0.47 |
|
2009 |
Becker M, Ibrahim Y, Byron S, Sarver A, Silverstein K, Lee A, Yee D. IGF-Induced Gene Profiles Are Dependent on IRS Expression and Convey Prognostic Value in Human Breast Cancer. Cancer Research. 69: 3031-3031. DOI: 10.1158/0008-5472.Sabcs-09-3031 |
0.726 |
|
2009 |
Yee D, Zhang X, LaPara K, Fagan D, Ibrahim Y, Zhang H, Zeng X, Becker M, Sachdev D. 58 Inhibition of IGF signalling as cancer therapy European Journal of Cancer Supplements. 7: 17. DOI: 10.1016/S1359-6349(09)70061-8 |
0.672 |
|
Show low-probability matches. |